Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells

Journal of Immunology

Volumn 187, Issue 4, 2011, Pages 2015-2022

  Penaranda, Cristina ^a   Tang, Qizhi ^a,b   Bluestone, Jeffrey A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CASPASE 3; CD4 ANTIGEN; FAS ANTIGEN; MONOCLONAL ANTIBODY CD3; PROTEIN BCL 2; PROTEIN HELIOS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELLULAR IMMUNITY; CONTROLLED STUDY; EFFECTOR CELL; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; THYMUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DNA-BINDING PROTEINS; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; T-LYMPHOCYTES, REGULATORY; THYMUS GLAND; TRANSCRIPTION FACTORS;

EID: 80051931752     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1100713     Document Type: Article

References (37)

1. Chatenoud, L., and J. A. Bluestone. 2007. CD3-specific antibodies: A portal to the treatment of autoimmunity. Nat. Rev. Immunol. 7: 622-632. (Pubitemid 47123550)
2. Cosimi, A. B., R. B. Colvin, R. C. Burton, H. J. Winn, R. Rubin, G. Goldstein, P. C. Kung, R. A. Hoffman, W. P. Hansen, and P. S. Russell. 1981. Immunologic monitoring with monoclonal antibodies to human T-cell subsets. Transplant. Proc. 13: 1589-1593. (Pubitemid 11016727)
3. Abramowicz, D., L. Schandene, M. Goldman, A. Crusiaux, P. Vereerstraeten, L. De Pauw, J. Wybran, P. Kinnaert, E. Dupont, and C. Toussaint. 1989. Release of tumor necrosis factor, interleukin-2, and g-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47: 606-608. (Pubitemid 19110914)
4. Chatenoud, L., C. Ferran, A. Reuter, C. Legendre, Y. Gevaert, H. Kreis, P. Franchimont, and J. F. Bach. 1989. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-g. [corrected] N. Engl. J. Med. 320: 1420-1421. (Pubitemid 19138943)
5. Alegre, M. L., J. Y. Tso, H. A. Sattar, J. Smith, F. Desalle, M. Cole, and J. A. Bluestone. 1995. An anti-murine CD3 monoclonal antibody with a low affinity for Fcg receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 155: 1544-1555.
6. Alegre, M. L., A. M. Collins, V. L. Pulito, R. A. Brosius, W. C. Olson, R. A. Zivin, R. Knowles, J. R. Thistlethwaite, L. K. Jolliffe, and J. A. Bluestone.1992. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J. Immunol. 148: 3461-3468.
7. Friend, P. J., G. Hale, L. Chatenoud, P. Rebello, J. Bradley, S. Thiru, J. M. Phillips, and H. Waldmann. 1999. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68: 1632-1637. (Pubitemid 30004793)
8. Woodle, E. S., J. R. Thistlethwaite, I. A. Ghobrial, L. K. Jolliffe, F. P. Stuart, and J. A. Bluestone. 1991. OKT3 F(ab9)2 fragments: Retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. Transplantation 52: 354-360.
9. Woodle, E. S., D. Xu, R. A. Zivin, J. Auger, J. Charette, R. O'Laughlin, D. Peace, L. K. Jollife, T. Haverty, J. A. Bluestone, and J. R. Thistlethwaite Jr. 1999. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3g1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68: 608-616. (Pubitemid 29453435)
10. Smith, J. A., Q. Tang, and J. A. Bluestone. 1998. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J. Immunol. 160: 4841-4849. (Pubitemid 28215318)
11. Smith, J. A., J. Y. Tso, M. R. Clark, M. S. Cole, and J. A. Bluestone. 1997. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J. Exp. Med. 185: 1413-1422. (Pubitemid 27187598)
12. Herold, K. C., J. B. Burton, F. Francois, E. Poumian-Ruiz, M. Glandt, and J. A. Bluestone. 2003. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3g1(Ala-Ala). J. Clin. Invest. 111: 409-418. (Pubitemid 36182218)
13. Chatenoud, L., J. Primo, and J. F. Bach. 1997. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158: 2947-2954. (Pubitemid 127470558)
14. Brusko, T. M., A. L. Putnam, and J. A. Bluestone. 2008. Human regulatory T cells: Role in autoimmune disease and therapeutic opportunities. Immunol. Rev. 223: 371-390. (Pubitemid 351986182)
15. + regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9: 239-244.
16. Belghith, M., J. A. Bluestone, S. Barriot, J. Mégret, J. F. Bach, and L. Chatenoud. 2003. TGF-b-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9: 1202-1208. (Pubitemid 37173706)
17. Bresson, D., L. Togher, E. Rodrigo, Y. Chen, J. A. Bluestone, K. C. Herold, and M. Von Herrath. 2006. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 116: 1371-1381.
18. + T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J. Immunol. 174: 4525-4534.
19. Chen, G., G. Han, J. Wang, R. Wang, R. Xu, B. Shen, J. Qian, and Y. Li. 2008. Essential roles of TGF-β in anti-CD3 antibody therapy: Reversal of diabetes in nonobese diabetic mice independent of Foxp3+CD4+ regulatory T cells. J. Leukoc. Biol. 83: 280-287. (Pubitemid 351225608)
20. Yang, W., S. Hussain, Q. S. Mi, P. Santamaria, and T. L. Delovitch. 2004. Perturbed homeostasis of peripheral T cells elicits decreased susceptibility to anti-CD3-induced apoptosis in prediabetic nonobese diabetic mice. J. Immunol. 173: 4407-4416. (Pubitemid 39280670)
21. Mandala, S., R. Hajdu, J. Bergstrom, E. Quackenbush, J. Xie, J. Milligan, R. Thornton, G. J. Shei, D. Card, C. Keohane, et al. 2002. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349. (Pubitemid 34303689)
22. Green, D. R. 2003. Overview: Apoptotic signaling pathways in the immune system. Immunol. Rev. 193: 5-9. (Pubitemid 36688034)
23. Hildeman, D., T. Jorgensen, J. Kappler, and P. Marrack. 2007. Apoptosis and the homeostatic control of immune responses. Curr. Opin. Immunol. 19: 516-521. (Pubitemid 47464912)
24. Hildeman, D. A., Y. Zhu, T. C. Mitchell, P. Bouillet, A. Strasser, J. Kappler, and P. Marrack. 2002. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity 16: 759-767. (Pubitemid 34786475)
25. Tang, Q., J. A. Smith, G. L. Szot, P. Zhou, M. L. Alegre, K. J. Henriksen, C. B. Thompson, and J. A. Bluestone. 2003. CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo. J. Immunol. 170: 1510-1516. (Pubitemid 36139522)
26. Núñez, G., R. Merino, D. Grillot, and M. González-García. 1994. Bcl-2 and Bclx: Regulatory switches for lymphoid death and survival. Immunol. Today 15: 582-588. (Pubitemid 24353910)
27. Woo, M., R. Hakem, M. S. Soengas, G. S. Duncan, A. Shahinian, D. Kägi, A. Hakem, M. McCurrach, W. Khoo, S. A. Kaufman, et al. 1998. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev. 12: 806-819. (Pubitemid 28150882)
28. Zhou, X., S. L. Bailey-Bucktrout, L. T. Jeker, C. Penaranda, M. Martínez- Llordella, M. Ashby, M. Nakayama, W. Rosenthal, and J. A. Bluestone. 2009. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10: 1000-1007.
29. + T regulatory cells. J. Immunol. 184: 3433-3441.
30. Von Herrath, M. G., B. Coon, T. Wolfe, and L. Chatenoud. 2002. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J. Immunol. 168: 933-941. (Pubitemid 34049598)
31. + CD4 T cells. Ann. N. Y. Acad. Sci. 1103: 167-178.
32. Puthalakath, H., and A. Strasser. 2002. Keeping killers on a tight leash: Transcriptional and post-translational control of the pro-apoptotic activity of BH3- only proteins. Cell Death Differ. 9: 505-512. (Pubitemid 34521178)
33. + T regulatory cells in mice. Cell. Mol. Immunol. 7: 419-427.
34. Tang, Q., J. Y. Adams, C. Penaranda, K. Melli, E. Piaggio, E. Sgouroudis, C. A. Piccirillo, B. L. Salomon, and J. A. Bluestone. 2008. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28: 687-697.
35. McClymont, S. A., A. L. Putnam, M. R. Lee, J. H. Esensten, W. Liu, M. A. Hulme, U. Hoffmüller, U. Baron, S. Olek, J. A. Bluestone, and T. M. Brusko. 2011. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 186: 3918-3926.
36. + Tregs. J. Clin. Invest. 115: 2904-2913.
37. Walker, M. R., D. J. Kasprowicz, V. H. Gersuk, A. Benard, M. Van Landeghen, J. H. Buckner, and S. F. Ziegler. 2003. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J. Clin. Invest. 112: 1437-1443. (Pubitemid 38057697)